About this Research Topic
The advent of next generation sequencing has broadened the horizon of the landscape of genetic, epigenetic and transcriptomic information that is available for probing the subgroups of patients suffering from any specific disease. However, there is still a need to explore the genomic, proteomic, structural and systems biology based data for the development of effective and reliable tools to prevent, diagnose, and treat NTDs.
This Research Topic aims to collect cutting edge research from a number of institutions and research groups, who have dedicated their notable work to develop approaches to fighting NTDs, such as vaccines, diagnostics, and medicines.
We will welcome manuscripts having multidisciplinary content, exploring diverse knowledge of genomes for NTDs causing species and discovering allosteric modulators of therapeutically important targets. The use of genetic next generation sequencing datasets, transcriptome-based characterization of pathway activities, host immune system relationship, pharmacokinetics properties of drug acting against NTDs are also welcome.
The neglected tropical diseases (NTDs) are very heterogeneous and consequently the analysis of inequity and social determinants is extraordinarily complex. NTDs include 13 diseases, defined by the World Health Organization (WHO) Department of Neglected Tropical Diseases: Buruli ulcer, Chagas disease, dracunculiasis, lymphatic filariasis, human African trypanosomiasis, dengue fever, cholera, leishmaniasis, leprosy, schistosomiasis, onchocerciasis, soil-transmitted helminths and trachoma.
Authors working on any of the above listed diseases can submit their research work in this issue. Although studies may mainly rely on computational models, authors are required to further validate the findings. Submitted articles should be related to different / novel computational approaches covering the following subtopics:
· Biomarkers, patient selection methods
· Metabolic pathways analysis for host as well as pathogens
· Transcriptomic markers of disease phenotypes
· Protein families as important drug targets
· Inhibitor development and challenges
Dr. Rajagopal is employed for Denovo Biopharma, San Diego, USA. The other Topic Editors declare no conflict of interest regarding the Research Topic theme
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.